OptimizeRx Corp [OPRX] stock is trading at $16.18, down -6.47%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OPRX shares have gain 25.82% over the last week, with a monthly amount glided 27.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
OptimizeRx Corp [NASDAQ: OPRX] stock has seen the most recent analyst activity on January 08, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform and also revised its price target to $6 from $7. Previously, Stephens started tracking the stock with Equal-Weight rating on December 20, 2024, and set its price target to $5.50. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $15 on April 04, 2024. Barclays initiated its recommendation with a Equal Weight and recommended $15 as its price target on January 03, 2024. In a note dated November 01, 2022, Stifel initiated an Buy rating and provided a target price of $19 on this stock.
OptimizeRx Corp [OPRX] stock has fluctuated between $3.78 and $18.22 over the past year. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. OptimizeRx Corp [NASDAQ: OPRX] shares were valued at $16.18 at the most recent close of the market. An investor can expect a potential drop of -7.29% based on the average OPRX price forecast.
Analyzing the OPRX fundamentals
OptimizeRx Corp [NASDAQ:OPRX] reported sales of 104.75M for the trailing twelve months, which represents a growth of 55.19%. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -0.04%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.08 and Total Capital is -0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.04 points at the first support level, and at 13.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.38, and for the 2nd resistance point, it is at 18.57.
Ratios To Look Out For
For context, OptimizeRx Corp’s Current Ratio is 2.57. As well, the Quick Ratio is 2.57, while the Cash Ratio is 0.79. Considering the valuation of this stock, the price to sales ratio is 2.87, the price to book ratio is 2.52.
Transactions by insiders
Recent insider trading involved Lang James Paul, Director, that happened on Mar 14 ’25 when 0.32 million shares were purchased. CEO, FEBBO WILLIAM J completed a deal on Dec 12 ’24 to buy 20000.0 shares.
